Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › OCGN

Ocugen

OCGN Rare disease Lead: Phase 3 ★ Read the deep dive → 17 Biotech Distilled articles ↓ 50 filings & releases ↓ Cash $24.6M (Sep 30, 2026) ↓ 17 verdicts ↓ 6 timing quotes ↓
Infectious DiseaseOphthalmology CellGene TherapyProtein

Market cap $314M 339.3M shares (10-Q, Oct 30, 2026) × $0.925 close Nov 6, 2026

Most recent annual filing: 2026-03-04

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. Proposal 1 vote FDA decisionDec 22, 2026Proposal 1 vote FDA decision, Dec 22, 2026, material
  2. Reserved Share Proposal corporate updateDec 22, 2026Reserved Share Proposal corporate update, Dec 22, 2026, routine
  3. Governance/Authorized Shares corporate updateDec 22, 2026Governance/Authorized Shares corporate update, Dec 22, 2026, routine
  4. Corporate governance / cap tableDec 22, 2026Corporate governance / cap table, Dec 22, 2026, routine
  5. OCU400 Ph3 topline1Q 2027OCU400 Ph3 topline, 1Q 2027, thesis-defining
  6. Bahamas early-access program corporate update~Jan 2027Bahamas early-access program corporate update, ~Jan 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Novel Modifier Gene Therapy Platform · CanSino Biologics

Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach

Targets: NR2E3, RORA

Inhaled Mucosal Vaccine Platform · Washington University in St. Louis

Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza

Targets: SARS-CoV-2 Spike protein, influenza

modifier gene therapy platform

Gene-agnostic modifier gene therapy platform designed to address underlying disease biology and restore balance across multiple gene networks, enabling treatment of large patient populations with inherited retinal diseases and other causes of blindness including retinitis pigmentosa, Stargardt disease, and geographic atrophy/dry AMD

Targets: NR2E3

Inhaled Mucosal Vaccine Platform · National Institute of Allergy and Infectious Diseases

Next-generation inhaled mucosal vaccine platform; focus area: infectious diseases including COVID-19

Capital (as filed)

Cash
$24.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$59.6M Sep 30, 2026
Operating cash flow
−$15.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$84.6M cash, runway 2028 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (17)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (17 calls)

Every verdict Biotech Distilled has published on Ocugen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-21 Watch Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products For most investors, wait for the balance sheet to be repaired and dilution overhang removed; for aggressive traders only, a small speculative position is warranted ahead of near-term data catalysts.
  2. 2026-01-22 Speculative buy speculative CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper The clean $22.5M common stock raise with no warrants removes the immediate bankruptcy risk and warrant overhang, improving the risk/reward for those playing the upcoming data catalysts.
  3. 2026-03-08 Speculative buy speculative UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update Clinical thesis remains intact with a major Phase 2 GA data catalyst imminent, but the Delaware Chancery Court cap-table issue is a severe distraction that limits further equity raises until resolved.
  4. 2026-03-22 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama Institutional warrant exercise of $15M mid-Delaware-chaos signals the legal issue is a formality, and the extended runway into Q1 2027 allows the company to negotiate from stability ahead of clinical readouts.
  5. 2026-03-29 Speculative buy speculative UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In Full Phase 2 OCU410 data showing 31% lesion reduction with clean safety profile profoundly de-risks the scientific thesis and makes the asset a premier M&A target, though the May 6 Delaware hearing remains a shadow.
  6. 2026-04-27 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Reverse Split Cometh Clinical thesis has compounded with OCU410 data, OCU400 Phase 3 enrolled, and OCU410ST dosing complete, but governance risks from the reverse split and CEO mega-grant create wider volatility spread; aggressive holders should ride through the June 11 vote.
  7. 2026-05-04 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks) The $115M convertible offering wipes out the Avenue secured debt and extends runway plausibly into 2028, fundamentally changing the balance sheet from distressed to fortified, though convertible-arb pressure will create near-term headwinds.
  8. 2026-05-06 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds The 19.5% stock drop on convertible pricing is mechanical arb selling, not fundamental repricing; the financing risk is now bounded and the science is unchanged, making the drawdown a potential entry point.
  9. 2026-05-15 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks Full greenshoe exercise to $130M confirms institutional conviction, but the abrupt unexplained CMO departure two months before rolling BLA initiation adds a new governance question that warrants monitoring.
  10. 2026-06-11 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Annual Meeting That Didn't Mention the Reverse Split Genead made permanent CMO closes one open question, but the conspicuous absence of the reverse-split vote result leaves the convertible's stock-settlement mechanics and CEO comp penalty unresolved, pending clarifying disclosure.
  11. 2026-07-13 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Second Regional Deal Lands The MENA regional deal with 22% royalty and supply manufacturing tail confirms the partnership playbook is working and negotiating leverage has improved post-convertible, adding commercial validation ahead of the Phase 3 readout.
  12. 2026-07-30 Speculative buy speculative UPDATE: Ocugen (OCGN) – RMAT Lands, BlackRock Shows Up, Stock Doesn't Care FDA RMAT designation for OCU410 independently validates the Phase 2 clinical signal and Phase 3 design, while BlackRock's 8% stake adds a sixth smart-money signal, but the stock continues to trade on cap-table mechanics rather than clinical trajectory.
  13. 2026-08-07 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Rolling BLA Rolls Away Delaware legally resolved and September 21 reserved-share vote now dated, but the OCU400 rolling BLA has been structurally reframed to post-Phase 3 topline, removing the key Q3 de-risking waypoint and extending the data-free holding period to Q1 2027.
  14. 2026-09-02 Speculative buy speculative UPDATE: Ocugen (OCGN) – First Patient Dosed in ArMaDa3 ArMaDa3 first patient dosed on schedule confirms operational execution, but the September 21 reserved-share vote remains the gating structural event before the stock can trade on clinical trajectory rather than cap-table mechanics.
  15. 2026-09-23 Watch UPDATE: Ocugen (OCGN) - The Unlock Gets Postponed The September 21 reserved-share vote was adjourned without a tally, the stock sits on the $1.00 Nasdaq minimum, and management has now failed twice to close a needed shareholder vote, warranting a downgrade until October 5 resolves the governance question.
  16. 2026-10-07 Watch UPDATE: Ocugen (OCGN) - Adjourned Again The October 5 vote was adjourned a second time to October 26 with the same electorate, confirming the retail-voter structural problem persists; October 26 is now the deciding event between upgrading back to buy or downgrading to avoid.
  17. 2026-10-16 Avoid UPDATE: Ocugen (OCGN) - The Vote Slips to December The October 26 vote was cancelled and rescheduled to December 22 — nine days before the CEO cash-settlement deadline — marking the third delay since September 21; the stock has fallen below Nasdaq's $1.00 minimum bid, adding a listing-compliance risk on top of the unresolved cap-table overhangs.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (50)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)